Gemcitabine (hydrochloride) (Standard)

Gemcitabine (hydrochloride) (Standard) is the analytical standard of Gemcitabine (hydrochloride) . This product is intended for research and analytical applications. Gemcitabine Hydrochloride (LY 188011 Hydrochloride) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine Hydrochloride inhibits DNA synthesis and repair, resulting in autophagyand apoptosis[1][2].

Product Specifications

CAS Number

[122111-03-9]

Product Name Alternative

LY 188011 (hydrochloride) (Standard)

UNSPSC

12352005

Hazard Statement

H360

Target

Apoptosis; Autophagy; DNA/RNA Synthesis; Nucleoside Antimetabolite/Analog; Reference Standards

Type

Reference Standards

Related Pathways

Apoptosis; Autophagy; Cell Cycle/DNA Damage; Others

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/gemcitabine-hydrochloride-standard.html

Purity

99.94

Smiles

O[C@H]1C(F)(F)[C@H](N2C(N=C(N)C=C2)=O)O[C@@H]1CO.Cl

Molecular Formula

C9H12ClF2N3O4

Molecular Weight

299.66

Precautions

H360

References & Citations

[1]Wang H, et al. Enhanced efficacy of Gemcitabine by indole-3-carbinol in pancreatic cell lines: the role of human equilibrativenucleoside transporter 1. Anticancer Res. 2011 Oct;31 (10) :3171-80|[2]Gagnadoux F, et al. Safety of pulmonary administration of gemcitabine in rats. J Aerosol Med. 2005 Summer;18 (2) :198-206|[3]Lou M, et al. Physical interaction between human ribonucleotide reductase large subunit and thioredoxin increases colorectal cancer malignancy. J Biol Chem. 2017 Jun 2;292 (22) :9136-9149.|[4]Yip-Schneider MT, et al. Dimethylaminoparthenolide and Gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. BMC Cancer. 2013 Apr 17;13:194.